Connection
Michael Birrer to Administration, Oral
This is a "connection" page, showing publications Michael Birrer has written about Administration, Oral.
|
|
Connection Strength |
|
|
|
|
|
0.026 |
|
|
|
-
Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
Score: 0.026